Evidence from the literature indicates that a study has shown that anti–vascular endothelial growth factor (anti-VEGF) therapy generally does not lead to reperfusion of small retinal vessels in areas of nonperfusion, even though neovascularization regressed and diabetic retinopathy severity scale scores may improve [47]. The gene discussed is VEGFA; the disease is diabetic retinopathy.